Divine Skin Announces New Pain Reliever to Compete With Tylenol, Advil, Aspirin

MIAMI BEACH, Fla., June 13, 2011 /PRNewswire/ -- Today Divine Skin Inc. (DSKX), a developer of personal-care biotechnology, announced plans to release a new oral analgesic intended to compete over the counter with the likes of Tylenol, Advil, and aspirin. The company plans to begin shipping upon final authorization by the Drug Enforcement Administration.

"Since Divine Skin focuses on underserved and niche categories, of course our pain medication will offer patients some benefits that competitors don't. The product will give better pain relief, with a safety profile similar to that of Advil," explained Daniel Khesin, chairman and CEO.

"We certainly don't expect to take significant market share away from the huge players, since consumers have been taking Tylenol and Advil for generations. Instead, we will target an audience that appreciates more advanced biotechnology. If we win just one tenth of one percent of the market — which we will — then we'll be happy," he said.

In the United States alone, manufacturers' revenue from internal non-narcotic analgesics, antipyretics, antiarthritics, and anti-inflammatories, including salicylates and acetaminophen, totaled $2.4 billion in 2009, according to an August 2010 report published by the US Census Bureau.

Each patient responds differently to each type of pain and pain reliever. A few years ago, Khesin himself endured a grueling experience with chronic pain after suffering a catastrophic spinal cord injury, which put him in a wheelchair for months. During his recovery, he tried nearly all of the pain relievers then available, including some strong narcotics.

That ordeal, combined with his expertise in business development and the commercialization of new biotechnologies, resulted in what he believed might become a unique over-the-counter medication. Laboratory research showed promise for the new formula, and subsequent clinical studies confirmed the drug's effectiveness.

About Divine Skin

Divine Skin Inc. is a biotechnology company engaged in the development of topical therapies and over-the-counter drugs that can be brought to market quickly, without lengthy regulatory requirements. In its consumer division, the company develops, markets, and distributes personal-care products through cosmetics wholesalers, online retailers, specialty outlets, spas, salons, and medical offices in more than 20 countries. Its brands include DS Laboratories, Sigma Skin, Polaris Research Laboratories, and The Pure Guild.

DS Laboratories, the flagship brand, offers high-performance topical solutions for men and women to restore growth and radiance to hair, suppress dandruff and unwanted hair, control acne, maintain feminine hygiene, and reduce the appearance of cellulite, wrinkles, and double chins (www.dslaboratories.com).

The Sigma Skin brand targets men and sells through upscale retailers such as Bergdorf Goodman and Neiman Marcus in the United States, Saks Fifth Avenue in Mexico, and Harvey Nichols in the United Kingdom. Products are designed to reverse hair loss and other signs of aging (www.sigmaskin.com).

Polaris Research Laboratories makes high-potency minoxidil-based hair-growth formulas (www.polarisresearchlabs.com).

The Pure Guild, the newest brand, offers purity with performance. The botanical compounds proven most effective in rigorous clinical trials are extracted mechanically, using no industrial solvents or damaging heat. The uncompromised treatments sell through ultra-premium food retailers (www.thepureguild.com).

Divine Skin's management believes the company has established itself as a leader in topical therapies, especially hair growth, through aggressive pursuit of innovation and technology. Products employ comprehensive formulas with multiple methods of action against common skin conditions. Many utilize proprietary encapsulation techniques for improved bioavailability.

SOURCE Divine Skin Inc.

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.